MDT Filing
4Filing Date: Aug 4, 2026

Medtronic plc (MDT) · Insider Trading (Form 4) SEC Filing

Statement of Changes in Beneficial Ownership

descriptionView SEC Filing
ACC: 0001708062-26-000010open_in_new
Total Value$262.5K
Trades4
Insiders1

Transaction Details

KIIL HARRY SKIP
EVP & President Cardiovascular·Direct
Grant · Acquire
Stock Option (Right to Buy)Derivative
Shares+65.56K
Price$0.00
Total Value$0
Shares Owned After65.56K
Transaction DateAug 3, 2026
ExpiresAug 3, 2036
Footnotes ▸

These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant.

KIIL HARRY SKIP
EVP & President Cardiovascular·Direct
Grant · Acquire
Ordinary Shares
Shares+9.23K
Price$0.00
Total Value$0
Shares Owned After43.67K
Transaction DateAug 3, 2026
Footnotes ▸

Represents restricted stock units that vest 100% on the third anniversary of the date of grant.

KIIL HARRY SKIP
EVP & President Cardiovascular·Direct
Grant · Acquire
Performance Share UnitsDerivative
Shares+23.07K
Price$0.00
Total Value$0
Shares Owned After23.07K
Transaction DateAug 3, 2026
Footnotes ▸

Each performance share unit represents a contingent right to receive one share of Medtronic common stock. | Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. | Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. | The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 23,074 shares will be issued. If maximum performance metrics are achieved, 55,378 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares.

KIIL HARRY SKIP
EVP & President Cardiovascular·Direct
Tax W/H · Dispose
Ordinary Shares
Shares-3.07K
Price$85.39
Total Value$262.5K
Shares Owned After34.44K
Transaction DateJul 31, 2026
Footnotes ▸

Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I. | Includes 286 shares acquired through dividend reinvestment since the last report filed by the reporting person.

Post-Transaction Holdings

KIIL HARRY SKIP
SecuritySharesChange
Ordinary Shares43.67K+6.16K (16.41%)
Performance Share Units23.07K+23.07K
Stock Option (Right to Buy)65.56K+65.56K
Original SEC Filing Textexpand_more
=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-07-31 10b5-1 Pre-arranged Plan: No --- Issuer --- Name: Medtronic plc (MDT) CIK: 0001613103 --- Reporting Owner --- Name: KIIL HARRY SKIP CIK: 0001708062 Role: Officer (EVP & President Cardiovascular) --- Non-Derivative Transactions --- [Transaction #1] Security: Ordinary Shares Date: 2026-07-31 | Code: F (Payment of exercise/tax) Shares: -3,074 | Price: $85.39 Total Value: $262,488.86 Shares Owned After: 34,439 | Ownership: D (Direct) Footnotes: [F1] Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I. [F2] Includes 286 shares acquired through dividend reinvestment since the last report filed by the reporting person. [Transaction #2] Security: Ordinary Shares Date: 2026-08-03 | Code: A (Grant or award) Shares: +9,230 | Price: $0.00 Shares Owned After: 43,669 | Ownership: D (Direct) Footnotes: [F3] Represents restricted stock units that vest 100% on the third anniversary of the date of grant. --- Derivative Transactions --- [Transaction #1] Security: Performance Share Units Date: 2026-08-03 | Code: A (Grant or award) Shares: +23,074 | Price: $0.00 Shares Owned After: 23,074 | Ownership: D (Direct) Footnotes: [F4] Each performance share unit represents a contingent right to receive one share of Medtronic common stock. [F5] Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. [F5] Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. [F6] The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 23,074 shares will be issued. If maximum performance metrics are achieved, 55,378 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. [Transaction #2] Security: Stock Option (Right to Buy) Date: 2026-08-03 | Code: A (Grant or award) Shares: +65,556 | Price: $0.00 Exercisable: N/A | Expires: 2036-08-03 Shares Owned After: 65,556 | Ownership: D (Direct) Footnotes: [F7] These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. --- Footnotes (Complete Index) --- F1: Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I. F2: Includes 286 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3: Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5: Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 23,074 shares will be issued. If maximum performance metrics are achieved, 55,378 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. --- Signature --- /s/ /s/ Patricia Walesiewicz, attorney-in-fact (2026-08-04)

keid analysis is for reference only and does not constitute investment advice.